IMAB - I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

• Chinese biotech I-Mab ( NASDAQ: IMAB ) on Tuesday said it got local regulatory approval to start a phase 3 trial evaluating its antibody lemzoparlimab in combination with cancer drug azacitidine for the treatment of myelodysplastic syndrome (MDS).
• MDS is a group of cancers caused due to blood cells that are poorly formed or don't work properly.
• The approval to start the trial follows a successful completion of an end-of-phase 2 meeting with the Center for Drug Evaluation of China's National Medical Products Administration, IMAB said in a statement .
• The meeting was supported by results from a phase 2 trial assessing lemzoparlimab in combination with azacitidine for the treatment of patients with newly diagnosed higher-risk MS, IMAB said.
• The company said it is on track to initiate the late-stage study as planned.
• U.S.-listed shares of IMAB -4.8% at $5.31 in morning trading.

For further details see: